Mental Health in Urologic Oncology
This article is a systematic review of mental health in urologic oncology patients with prostate cancer (PCa), bladder cancer (BC), renal cell carcinoma (RCC), testicular cancer (TC), or penile cancer (PeCa). For all pathologies, a focus on increasing quality of life post-treatment demonstrated a positive impact in reducing Mental Health Illness (MHI) prevalence. Cancer specific mental health care may be given to patients to reduce suicide risk in BC patients and sexual identify and masculinity counseling may improve mental health for TC or PeCa patients. In order to better accommodate patient’s mental health needs when undergoing GU cancer treatment, we recommend incorporation of mental health metrics such as questionnaires to assess early treatment of MHI, a greater emphasis on psychosocial support with the patient’s loved ones, peers, and healthcare team, alongside advising healthy habits such as exercise which has been shown to drastically reduce MHI incidence across all pathologies. We hope that these measures conducted by urologists and oncologists, alongside possible coordination with psychiatrists and psychologists for psychotherapy, psychopharmacology, and neuro-stimulation treatment modems may be helpful in the long term to reduce MHI incidence in urology oncology patients. Given the higher incidence of MHI in oncology patients and in the patient population after the Covid-19 pandemic, MHI awareness in the sphere of urologic oncologic treatment continues to be crucial when creating a collaborative treatment platform for patients.
1. Shah SMA, Mohammad D, Qureshi MFH, Abbas MZ, Aleem S.Prevalence, Psychological Responses and Associated Correlates of Depression, Anxiety and Stress in a Global Population, During the Coronavirus Disease (COVID-19) Pandemic. Community Ment Health J. 2021;57(1):101-110. doi:10.1007/s10597-020-00728-y
2. Cooke JE, Eirich R, Racine N, Madigan S.Prevalence of posttraumatic and general psychological stress during COVID-19: A rapid review and meta-analysis. Psychiatry Res. 2020;292(113347):113347. doi:10.1016/j.psychres.2020.113347
3. Krebber AMH, Buffart LM, Kleijn G, et al.Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014;23(2):121-130. doi:10.1002/pon.3409
4. Mitchell AJ, Chan M, Bhatti H, et al.Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160-174. doi:10.1016/s1470-2045(11)70002-x
5. Waraich P, Goldner EM, Somers JM, Hsu L.Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry. 2004;49(2):124-138. doi:10.1177/070674370404900208
6. Klaassen Z, Wallis CJD, Chandrasekar T, et al.Cancer diagnosis and risk of suicide after accounting for prediagnosis psychiatric care: A matched-cohort study of patients with incident solid-organ malignancies. Cancer. 2019;125(16):2886-2895. doi:10.1002/cncr.32146
7. Grassi L.Psychiatric and psychosocial implications in cancer care: the agenda of psycho-oncology. Epidemiol Psychiatr Sci. 2020;29. doi:10.1017/s2045796019000829
8. Ramakrishnan VM, Trinh QD.Suicide Risk Among Patients with Genitourinary Malignancies: Where Do We Stand? Eur Urol Focus. 2020;6(6):1145-1146. doi:10.1016/j.euf.2019.09.007
9. Siebert AL, Lapping-Carr L, Morgans AK.Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician. Eur Urol Focus. 2020;6(6):1170-1179. doi:10.1016/j.euf.2020.05.014
10. Klaassen Z, Wallis CJD, Goldberg H, et al.The impact of psychiatric utilisation prior to cancer diagnosis on survival of solid organ malignancies. Br J Cancer. 2019;120(8):840-847. doi:10.1038/s41416-019-0390-0
11. Klaassen Z, Jen RP, DiBianco JM, et al.Factors associated with suicide in patients with genitourinary malignancies. Cancer. 2015;121(11):1864-1872. doi:10.1002/cncr.29274
12. Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
13. Siegel RL, Miller KD, Fuchs HE, Jemal A.Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/caac.21708
14. Steele CB, Li J, Huang B, Weir HK.Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study. Cancer. 2017;123(Suppl 24):5160-5177. doi:10.1002/cncr.31026
15. Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A.Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev. 2014;15(22):9575-9578. doi:10.7314/apjcp.2014.15.22.9575
16. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E.Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst. 2000;92(24):2009-2017. doi:10.1093/jnci/92.24.2009
17. Bree KK, Hensley PJ, Pettaway CA.Germline Mutations in African American Men With Prostate Cancer: Incidence, Implications and Diagnostic Disparities. Urology. 2021;163:148-155. doi:10.1016/j.urology.2021.08.017
18. Wang G, Zhao D, Spring DJ, DePinho RA.Genetics and biology of prostate cancer. Genes Dev. 2018;32(17-18):1105-1140. doi:10.1101/gad.315739.118
19. Parnham A, Serefoglu EC.Retrograde ejaculation, painful ejaculation and hematospermia. Transl Androl Urol. 2016;5(4):592-601. doi:10.21037/tau.2016.06.05
20. Suzman DL, Boikos SA, Carducci MA.Bone-targeting agents in prostate cancer. Cancer Metastasis Rev. 2014;33(2-3):619-628. doi:10.1007/s10555-013-9480-2
21. Wallace TJ, Torre T, Grob M, et al.Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer. 2014;5(1):3-24. doi:10.7150/jca.7709
22. Cuzick J, Thorat MA, Andriole G, et al.Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15(11):e484-e492. doi:10.1016/s1470-2045(14)70211-6
23. Leslie SW, Soon-Sutton TL, Sajjad H, Siref LE.Prostate Cancer. Statpearls Publishing; 2022.
24. Toivanen R, Shen MM.Prostate organogenesis: tissue induction, hormonal regulation and cell type specification. Development. 2017;144(8):1382-1398. doi:10.1242/dev.148270
25. Abate-Shen C, Shen MM.Molecular genetics of prostate cancer. Genes Dev. 2000;14(19):2410-2434. doi:10.1101/gad.819500
26. Garraway IP, Sun W, Tran CP, et al.Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate. 2010;70(5):491-501. doi:10.1002/pros.21083
27. Lee SH, Shen MM.Cell types of origin for prostate cancer. Curr Opin Cell Biol. 2015;37:35-41. doi:10.1016/j.ceb.2015.10.002
28. Castillejos-Molina RA, Gabilondo-Navarro FB.Prostate cancer. Salud Publica Mex. 2016;58(2):279-284. doi:10.21149/spm.v58i2.7797
29. Gallagher DJ, Gaudet MM, Pal P, et al.Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010;16(7):2115-2121. doi:10.1158/1078-0432.ccr-09-2871
30. Bancroft EK, Page EC, Brook MN, et al.A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): Initial results from an international prospective study. Lancet Oncol. 2021;22(11):1618-1631. doi:10.1016/s1470-2045(21)00522-2
31. Sinha R, Park Y, Graubard BI, et al.Meat and meat-related compounds and risk of prostate cancer in a large prospective cohort study in the United States. Am J Epidemiol. 2009;170(9):1165-1177. doi:10.1093/aje/kwp280
32. Colli JL, Colli A.International comparisons of prostate cancer mortality rates with dietary practices and sunlight levels. Urol Oncol. 2006;24(3):184-194. doi:10.1016/j.urolonc.2005.05.023
33. Downer MK, Kenfield SA, Stampfer MJ, et al.Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study. J Clin Oncol. 2019;37(17):1499-1511. doi:10.1200/jco.18.02462
34. Wilson KM, Kasperzyk JL, Rider JR, et al.Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst. 2011;103(11):876-884. doi:10.1093/jnci/djr151
35. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ.Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100(3):170-183. doi:10.1093/jnci/djm323
36. Mohamed NE, Bovbjerg DH, Montgomery GH, Hall SJ, Diefenbach MA.Pretreatment depressive symptoms and treatment modality predict post-treatment disease-specific quality of life among patients with localized prostate cancer. Urol Oncol. 2012;30(6):804-812. doi:10.1016/j.urolonc.2011.02.002
37. Moodie L, Ilie G, Rutledge R, Andreou P, Kirkland S.Assessment of Current Mental Health Status in a Population-Based Sample of Canadian Men With and Without a History of Prostate Cancer Diagnosis: An Analysis of the Canadian Longitudinal Study on Aging (CLSA). Front Psychiatry. 2020;11(586260). doi:10.3389/fpsyt.2020.586260
38. Ravi P, Karakiewicz PI, Roughmann F, et al.Mental health outcomes in elderly men with prostate cancer. Urol Oncol. 2014;32(8):1333-1340. doi:10.1016/j.urolo nc.2014.05.005
39. Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll PR, Cooperberg MR.A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int. 2013;112(2):E67-E75. doi:10.1111/bju.12209
40. Parker PA, Davis JW, Latini DM, et al.Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016;117(3):469-477. doi:10.1111/bju.13099
41. Peard L, Falkenstrom A, Klaassen Z, Terris MK.Re: Mental Health Outcomes in Elderly Men with Prostate Cancer. Eur Urol. 2016;70(1):206-207. doi:10.1016/j.eururo.2016.03.061
42. Deka R, Rose BS, Bryant AK, et al.Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy. Cancer. 2019;125(7):1070-1080. doi:10.1002/cncr.31982
43. Shin D, Shim SR, Kim CH.Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy. PLoS One. 2020;15(6):e0234264. doi:10.1371/journal.pone.0234264
44. Matta R, Wallis CJD, Goldenberg MG, et al.Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study. Eur Urol. 2019;75(1):3-7. doi:10.1016/j.eururo.2018.08.035
45. Vale S.Re: Rano Matta, Christopher J.D. Wallis, Mitchell G. Goldenberg, et al. Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study. Eur Urol. 2019;75:3-7: Translational Potential of Dual Detection: Depression Diagnosis plus Sense of Coherence Determination in Prostate Cancer. Eur Urol. 2019;75(6):e168-e169. doi:10.1016/j.eururo.2019.01.043
46. Ilie G, Rutledge R, Sweeney E.Post-Treatment Adverse Health Correlates among Prostate Cancer Survivors in a Sample of Men Residing in Atlantic Canada. Curr Oncol. 2021;28(4):2812-2822.doi:10.3390/curroncol28040246
47. Steginga SK, Occhipinti S, Gardiner RAF, Yaxley J, Heathcote P.Prospective study of men's psychological and decision-related adjustment after treatment for localized prostate cancer. Urology. 2004;63(4):751-756. doi:10.1016/j.urology.2003.11.017
48. Chambers SK, Ferguson M, Gardiner RA, Aitken J, Occhipinti S.Intervening to improve psychological outcomes for men with prostate cancer. Psychooncology. 2012;22(5):1025-1034. doi:10.1002/p on.3095
49. Toohey K, McKune A, Nahon I, Kavanagh PS, Newton RU, Paterson C.Improving Physical and Mental Health in Patients with Prostate Cancer Undergoing Androgen Deprivation Therapy: Strategies to Promote and Improve Physical Activity Quality and Quantity. Semin Oncol Nurs. 2020;36(4):151051. doi:10.1016/j.soncn.2020.151051
50. Zopf EM, Newton RU, Taaffe DR, et al.Associations between aerobic exercise levels and physical and mental health outcomes in men with bone metastatic prostate cancer: a cross-sectional investigation. Eur J Cancer Care. 2016;26(6). doi:10.1111/ecc.12575
51. Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A.Epidemiology of Bladder Cancer. Med Sci. 2020;8(1):15. doi:10.3390/medsci8010015
52. Greiman AK, Rosoff JS, Prasad SM.Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality. BJU Int. 2017;120(6):799-807. doi:10.1111/bju.13875
53. Pham H, Torres H, Sharma P.Mental health implications in bladder cancer patients: A review. Urol Oncol. 2019;37(2):97-107. doi:10.1016/j.urolon c.2018.12.006
54. Raphael MJ, Griffiths R, Peng Y, et al.Mental Health Resource Use Among Patients Undergoing Curative Intent Treatment for Bladder Cancer. J Natl Cancer Inst. 2021;113(9):1238-1245. doi:10.1093/jnci/djab026
55. Sathianathen NJ, Fan Y, Jarosek SL, et al.Disparities in Bladder Cancer Treatment and Survival Amongst Elderly Patients with a Pre-existing Mental Illness. Eur Urol Focus. 2020;6(6):1180-1187. doi:10.1016/j.euf.2019.02.007
56. Cooke IJ, Patil D, Bobrek K, et al.Longitudinal impact of bladder cancer diagnosis on common psychiatric disorders. Cancer Med. 2021;10(23):8412-8420. doi:10.1002/cam4.4346
57. Jazzar U, Yong S, Klaassen Z, et al.Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. Cancer. 2018;124(15):3127-3135. doi:10.1002/cncr.31404
58. Heyes SM, Bond MJ.Pathways to psychological wellbeing for patients with bladder cancer and their partners-in-care. Eur J Oncol Nurs. 2020;46(101757):101757. doi:10.1016/j.ejon.2020.101757
59. Mani J, Neuberth MT, Fettel J, Senf B, Khoder W, Vallo S.Quality of Patient Information by Urologists Is Associated with Mental Distress in Bladder Cancer Patients. Oncol Res Treat. 2020;43(5):228-236. doi:10.1159/000507094
60. Bessa A, Rammant E, Enting D, et al.The need for supportive mental wellbeing interventions in bladder cancer patients: A systematic review of the literature. PLoS One. 2021;16(1):e0243136. doi:10.1371/journa l.pone.0243136
61. Bessa A, Martin R, Haggstrom C, et al.Unmet needs in sexual health in bladder cancer patients: a systematic review of the evidence. BMC Urol. 2020;20(1):64. doi:10.1186/s12894-020-00634-1
62. Qian Z, Ding W, Zhou Q, Sun C, Xu K.Depression Induced by CUMS Leads to Bladder Cancer Development and Local Tumor Immunosuppression in Mice. J Oncol. 2021;2021(5537523):1-10. doi:10.1155/2021/5537523
63. Chow WH, Dong LM, Devesa SS.Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245-257. doi:10.1038/nrurol.2010.46
64. Capitanio U, Bensalah K, Bex A, et al.Epidemiology of Renal Cell Carcinoma. Eur Urol. 2019;75(1):74-84. doi:10.1016/j.eururo.2018.08.036
65. Rossi SH, Klatte T, Stewart GD.Quality of life outcomes in patients with localised renal cancer: A literature review. World J Urol. 2018;36(12):1961-1972. doi:10.1007/s00345-018-2415-3
66. Bhandari NR, Ounpraseuth ST, Kamel MH, et al.Changes in health-related quality of life outcomes in older patients with kidney cancer: A longitudinal cohort analysis with matched controls. Urologic Oncology: Seminars and Original Investigations. 2020;38(11):852.e11-852.e20. doi:10.1016/j.urolonc.2020.08.015
67. Garg T, Young AJ, Kost KA, et al.Burden of Multiple Chronic Conditions among Patients with Urological Cancer. Journal of Urology. 2018;199(2):543-550. doi:10.1016/j.juro.2017.08.005
68. Miyake H, Harada Kichi, Kusuda Y, Fujisawa M.Health-related quality of life in Japanese patients with metastatic renal cell carcinoma treated with sunitinib. Int J Clin Oncol. 2011;18(2):220-225. doi:10.1007/s10147-011-0364-6
69. Demirtas T, Temircan Z.Examining the Relationship between Depression, Anxiety and Stress in Kidney Cancer Patients. Journal of Kidney Cancer and VHL. 2021;9(1):19-26. doi:10.15586/jkcvhl.v9i1.199
70. Yang YL, Liu L, Li MY, Shi M, Wang L.Psychological Disorders and Psychosocial Resources of Patients with Newly Diagnosed Bladder and Kidney Cancer: A Cross-Sectional Study. PLoS ONE. 2016;11(5):e0155607. doi:10.1371/journal.pone.0155607
71. Shin DW, Park HS, Lee SH, et al.Health-Related Quality of Life, Perceived Social Support, and Depression in Disease-Free Survivors Who Underwent Curative Surgery Only for Prostate, Kidney and Bladder Cancer: Comparison among Survivors and with the General Population. Cancer Res Treat. 2019;51(1):289-299. doi:10.4143/crt.2018.053
72. Lee MJ, Huang CW, Chen YL, Yang YH, Chen VCH.Association between selective serotonin reuptake inhibitors and kidney cancer risk: A nationwide population-based cohort study. Int J Cancer. 2020;148(6):1331-1337. doi:10.1002/ijc.33307
73. Packiam VT, Tyson II MD, Tsivian M, et al.The association of anxiety and depression with perioperative and oncologic outcomes among patients with clear cell renal cell carcinoma undergoing nephrectomy. Urologic Oncology: Seminars and Original Investigations. 2020;38(2):41.e19-41.e27. doi:10.1016/j.urolonc.2019.10.017
74. Liu KL, Chuang CK, Pang ST, et al.Emotional state and cancer-related self-efficacy as affecting resilience and quality of life in kidney cancer patients: A cross-sectional study. Support Care Cancer. 2021;30(3):2263-2271. doi:10.1007/s00520-021-06644-5
75. Oberoi DV, White V, Jefford M, et al.Caregivers' information needs and their ‘experiences of care’ during treatment are associated with elevated anxiety and depression: a cross-sectional study of the caregivers of renal cancer survivors. Support Care Cancer. 2016;24(10):4177-4186. doi:10.1007/s00520-016-3245-8
76. Pastore AL, Mir A, Maruccia S, et al.Psychological distress in patients undergoing surgery for urological cancer: A single centre cross-sectional study. Urologic Oncology: Seminars and Original Investigations. 2017;35(12):673.e1-673.e7. doi:10.1016/j.urolonc.2017.08.006
77. Park JS, Kim J, Elghiaty A, Ham WS.Recent global trends in testicular cancer incidence and mortality. Medicine. 2018;97(37):e12390. doi:10.1097/md.0000000000012390
78. Baird DC, Meyers GJ, Hu JS.Testicular Cancer: Diagnosis and Treatment. Am Fam Physician. 2018;97(4):261-268.
79. Shaw J.Diagnosis and treatment of testicular cancer. Am Fam Physician. 2008;77(4):469-474.
80. Bosl GJ, Motzer RJ.Testicular Germ-Cell Cancer. N Engl J Med. 1997;337(4):242-254. doi:10.1056/nejm 199707243370406
81. Pettersson A, Richiardi L, Nordenskjold A, Kaijser M, Akre O.Age at Surgery for Undescended Testis and Risk of Testicular Cancer. N Engl J Med. 2007;356(18):1835-1841. doi:10.1056/nejmoa067588
82. Dieckmann KP, Ribe C, Henke RP.Association of Down's syndrome and testicular cancer. J Urol. 1997;157(5):1701-1704. doi:10.1016/s0022-5347(01)64838-9
83. Hasle H, Jacobsen BB, Asschenfeldt P, Andersen K.Mediastinal germ cell tumour associated with Klinefelter syndrome. Eur J Pediatr. 1992;151(10):735-739. doi:10.1007/bf01959079
84. Holzik MFL, Rapley E, Hoekstra H, Sleijfer D, Nolte I, Sijmons R.Genetic predisposition to testicular germ-cell tumours. The Lancet Oncology. 2004;5(6):363-371. doi:10.1016/s1470-2045(04)01493-7
85. Raman JD, Nobert CF, Goldstein M.Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. Journal of Urology. 2005;174(5):1819-1822. doi:10.1097/01.ju.0000177491.98461.aa
86. von der Maase H, Rorth M, Walbom-Jorgensen S, et al.Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. BMJ. 1986;293(6559):1398-1401. doi:10.1136/bmj.293.6559.1398
87. Tseng A, Horning SJ, Freiha FS, Resser KJ, Hannigan JF, Torti FM.Gynecomastia in testicular cancer patients prognostic and therapeutic implications. Cancer. 1985;56(10):2534-2538. doi:10.1002/1097-0142(19851115)56:10<2534::AID-CNCR2820561036>3.0.CO;2-Q
88. Dinesh AA, Helena Pagani Soares Pinto S, Brunckhorst O, Dasgupta P, Ahmed K.Anxiety, depression and urological cancer outcomes: A systematic review. Urol Oncol. 2021;39(12):816-828. doi:10.1016/j.urolonc.2021.08.003
89. Schepisi G, De Padova S, De Lisi D, et al.Psychosocial Issues in Long-Term Survivors of Testicular Cancer. Front Endocrinol. 2019;10. doi:10.3389/fendo.2019.00113
90. Dincer AN, Brunckhorst O, Genel O, Dasgupta P, Muneer A, Ahmed K.Quality of life, anxiety and depression patient-reported outcome measures in testicular cancer: A systematic review. Psychooncology. 2021;30(9):1420-1429. doi:10.1002/p on.5700
91. Alexis O, Adeleye AO, Worsley AJ.Men's experiences of surviving testicular cancer: An integrated literature review. J Cancer Surviv. 2019;14(3):284-293. doi:10.1007/s11764-019-00841-2
92. Amiri A, Chovanec M, Oliva V, et al.Chemotherapy-induced toxicity in patients with testicular germ cell tumors: The impact of physical fitness and regular exercise. Andrology. 2021;9(6):1879-1892. doi:10.1111/andr.13078
93. Osmańska M, Borkowska A, Makarewicz R. Evaluation of quality of life, anxiety and depression in testicular cancer patients during chemotherapy and after anticancer treatment. Psychiatr Pol. 2010;44(4):543-556.
94. Jovanovski A, Zugna D, di Cuonzo D, et al. Quality of life among germ-cell testicular cancer survivors: The effect of time since cancer diagnosis. PLoS ONE. 2021;16(10):e0258257. doi:10.1371/journal.pone.0258257
95. Skaali T, Fosså SD, Bremnes R, et al. Fear of recurrence in long-term testicular cancer survivors. Psycho-Oncology. 2009;18(6):580-588. doi:10.1002/pon.1437
96. Reilley M, Jacobs L, Vaughn D, Palmer S. Health behaviors among testicular cancer survivors. J Community Support Oncol. 2014;12(4):121-128. doi:10.12788/jcso.0033
97. ArdeshirRouhaniFard S, Dinh PC, Monahan PO, et al. Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study. Cancer Epidemiology, Biomarkers & Prevention. 2021;30(6):1129-1138. doi:10.1158/1055-9965.epi-20-1762
98. Grassi L, Caruso R, Hammelef K, Nanni MG, Riba M. Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: A review. International Review of Psychiatry. 2014;26(1):44-62. doi:10.3109/09540261.2013.842542
99. Andrade C. Antidepressants and Testicular Cancer: Cause Versus Association. J Clin Psychiatry. 2014;75(03):e198-e200. doi:10.4088/jcp.14f09056
100. Amiri A, Chovanec M, Oliva V, et al. Chemotherapy-induced toxicity in patients with testicular germ cell tumors: The impact of physical fitness and regular exercise. Andrology. 2021;9(6):1879-1892. doi:10.1111/andr.13078
101. Thorsen L, Nystad W, Stigum H, et al. The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Support Care Cancer. 2005;13(8):637-646. doi:10.1007/s00520-004-0769-0
102. Adams SC, DeLorey DS, Davenport MH, Fairey AS, North S, Courneya KS. Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors. Br J Cancer. 2018;118(10):1313-1321. doi:10.1038/s41416-018-0044-7
103. Petrella AR, Sabiston CM, Vani MF, Matthew A, Santa Mina D. Psychological Needs Satisfaction, Self-rated Health and the Mediating Role of Exercise Among Testicular Cancer Survivors. Am J Mens Health. 2021;15(2):155798832110126. doi:10.1177/15579883211012601
104. Tuinman MA, Hoekstra HJ, Fleer J, Sleijfer DTh, Hoekstra-Weebers JEHM. Self-esteem, social support, and mental health in survivors of testicular cancer: A comparison based on relationship status☆. Urologic Oncology: Seminars and Original Investigations. 2006;24(4):279-286. doi:10.1016/j.urolonc.2005.06.023
105. Sheppard C, Wylie KR. An assessment of sexual difficulties in men after treatment for testicular cancer. Sexual and Relationship Therapy. 2001;16(1):47-58. doi:10.1080/14681990124325
106. Raphael MJ, Gupta S, Wei X, et al. Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study. JCO. 2021;39(7):779-786. doi:10.1200/jco.20.02298
107. Douglawi A, Masterson TA. Penile cancer epidemiology and risk factors. Current Opinion in Urology. 2019;29(2):145-149. doi:10.1097/mou.0000000000000581
108. Hernandez BY, Barnholtz-Sloan J, German RR, et al. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer. 2008;113(S10):2883-2891. doi:10.1002/cncr.23743
109. Ritchie AWS, Foster PW, Fowler S. Penile cancer in the UK: clinical presentation and outcome in 1998/99. BJU Int. 2004;94(9):1248-1252. doi:10.1111/j.1464-410x.2004.05152.x
110. Heyns CF, Mendoza-Valdés A, Pompeo ACL. Diagnosis and Staging of Penile Cancer. Urology. 2010;76(2):S15-S23. doi:10.1016/j.urology.2010.03.002
111. Iorga L, Marcu R, Diaconu C, et al. Penile carcinoma and HPV infection (Review). Exp Ther Med. 2019;20(1):91-96. doi:10.3892/etm.2019.8181
112. Maden C, Sherman KJ, Beckmann AM, et al. History of Circumcision, Medical Conditions, and Sexual Activity and Risk of Penile Cancer. J Natl Cancer Inst. 1993;85(1):19-24. doi:10.1093/jnci/85.1.19
113. Barnes KT, McDowell BD, Button A, Smith BJ, Lynch CF, Gupta A. Obesity is associated with increased risk of invasive penile cancer. BMC Urol. 2016;16(1). doi:10.1186/s12894-016-0161-7
114. Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, de Sanjosé S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol. 2009;62(10):870-878. doi:10.1136/jcp.2008.063149
115. Harish K, Ravi R. The role of tobacco in penile carcinoma. British Journal of Urology. 1995;75(3):375-377. doi:10.1111/j.1464-410x.1995.tb07352.x
116. Stern RS. Genital Tumors among Men with Psoriasis Exposed to Psoralens and Ultraviolet A Radiation (PUVA) and Ultraviolet B Radiation. N Engl J Med. 1990;322(16):1093-1097. doi:10.1056/nejm199004193221601
117. Daling JR, Madeleine MM, Johnson LG, et al. Penile cancer: Importance of circumcision, human papillomavirus and smoking in situ and invasive disease. Int J Cancer. 2005;116(4):606-616. doi:10.1002/ijc.21009
118. Draeger DL, Sievert KD, Hakenberg OW. Cross-Sectional Patient-Reported Outcome Measuring of Health-Related Quality of Life With Establishment of Cancer- and Treatment-Specific Functional and Symptom Scales in Patients With Penile Cancer. Clinical Genitourinary Cancer. 2018;16(6):e1215-e1220. doi:10.1016/j.clgc.2018.07.029
119. Maddineni SB, Lau MM, Sangar VK. Identifying the needs of penile cancer sufferers: A systematic review of the quality of life, psychosexual and psychosocial literature in penile cancer. BMC Urol. 2009;9(1). doi:10.1186/1471-2490-9-8
120. Törnävä M, Harju E, Vasarainen H, Pakarainen T, Perttilä I, Kaipia A. Men’s experiences of the impact of penile cancer surgery on their lives: A qualitative study. European J Cancer Care. 2022;31(1). doi:10.1111/ecc.13548
121. Gulino G, Palermo G, D′Onofrio A, et al. Sexual outcomes after organ potency-sparing surgery and glans reconstruction in patients with penile carcinoma. Indian J Urol. 2013;29(2):119-123. doi:10.4103/0970-1591.114033
122. Harju E, Pakarainen T, Vasarainen H, et al. Health-Related Quality of Life, Self-esteem and Sexual Functioning Among Patients Operated for Penile Cancer – A Cross-sectional Study. The Journal of Sexual Medicine. 2021;18(9):1524-1531. doi:10.1016/j.jsxm.2021.06.015
123. Kieffer JM, Djajadiningrat RS, van Muilekom EAM, Graafland NM, Horenblas S, Aaronson NK. Quality of Life for Patients Treated for Penile Cancer. Journal of Urology. 2014;192(4):1105-1110. doi:10.1016/j.juro.2014.04.014
124. Sosnowski R, Wolski JK, Ziętalewicz U, Szymański M, Bakuła R, Demkow T. Assessment of selected quality of life domains in patients who have undergone conservative or radical surgical treatment for penile cancer: an observational study. Sex Health. 2019;16(1):32-38. doi:10.1071/sh17119
125. Witty K, Branney P, Evans J, Bullen K, White A, Eardley I. The impact of surgical treatment for penile cancer – Patients’ perspectives. European Journal of Oncology Nursing. 2013;17(5):661-667. doi:10.1016/j.ejon.2013.06.004
126. Dräger DL, Protzel C, Hakenberg OW. Identifying Psychosocial Distress and Stressors Using Distress-screening Instruments in Patients With Localized and Advanced Penile Cancer. Clinical Genitourinary Cancer. 2017;15(5):605-609. doi:10.1016/j.clgc.2017.04.010
127. Bullen K, Edwards S, Marke V, Matthews S. Looking past the obvious: experiences of altered masculinity in penile cancer. Psycho-Oncology. 2010;19(9):933-940. doi:10.1002/pon.1642
128. Pérez J, Chavarriaga J, Ortiz A, et al. Oncological and Functional Outcomes After Organ-Sparing Plastic Reconstructive Surgery for Penile Cancer. Urology. 2020;142:161-165.e1. doi:10.1016/j.urology.2020.03.058
129. Bergerot CD, Philip EJ, Bergerot PG, Pal SK. Distress and Quality of Life Among Patients with Advanced Genitourinary Cancers. Eur Urol Focus. 2020;6(6):1150-1154. doi:10.1016/j.euf.2019.10.014
130. Klaassen Z, Wallis CJD. Addressing Mental Health in Urology Patients: The Time is Now. Eur Urol Focus. 2020;6(6):1137-1139. doi:10.1016/j.euf.2020.08.009
131. Washington SLI, Nyame YA, Moses KA. What is the Impact of Racial Disparities on Diagnosis and Receipt of Appropriate Mental Health Care Among Urology Patients? Eur Urol Focus. 2020;6(6):1155-1157. doi:10.1016/j.euf.2019.08.017
132. Sekar R, Gore JL. Integration of Mental Health Metrics into Patient-centered Care of Urology Patients. Eur Urol Focus. 2020;6(6):1147-1149. doi:10.1016/j.euf.2020.04.003
133. Patel SB, McCall WV. Interface of Psychiatric Services with Urological Oncology Practice. Eur Urol Focus. 2020;6(6):1140-1141. doi:10.1016/j.euf.2020.04.002